StocksRunner logo
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  Highlights  
 
  Updates  
 
 
 
Viking Therapeutics
91.34
+7.18%
 

VKTX

 

Viking Therapeutics

$ 91.34

 
+$6.12 | +7.18%
 
 
Open
$ 90.00
 
 
MKT CAP
$ 9.18B
 
High
$ 94.67
 
 
VOL
$ 11.56M
 
Low
$ 86.23
 
 
AVG VOL
$ 7.50M
 
 
 

VKTX Stock Analysis

  Login to display Viking Therapeutics (VKTX) recommendation from the last 90 days from financial news and social media.
 
 

VKTX Total Score

 
 

Strengths

VKTX Rewards

 Trading below its fair value

VKTX Rewards

 Outperform the market

 

Risk Analysis

VKTX Risk Analysis

 Earnings are forecast to decrease

VKTX Risk Analysis

 Insider selling during the past 3 months

 
 

Chart

 
 

22.84

17.24

10.03

11

 
 
1month
3month
6month
1year
 
Total Return
VKTX
vs.
S&P500
 

 
1-week Return
+7.40%
 
+1.04%
 
 
5-week Return
+327.42%
 
+4.91%
 
 
10-week Return
+376.97%
 
+7.60%
 
 
 

VKTX Risk Level

This Indicator assigning VKTX risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
VKTX Risk Level
LOW
HIGH

Risk Volatility

 

VKTX has Low Risk Level

Click here to check what is your level of risk

 

VKTX Analysts Opinion

VKTX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

NA
 
 
 

Rating

×
 

Rating

NA
 
 

Momentum

×
 

Momentum

3.88
 

VKTX Momentum Analysis

 Has been gaining momentum

 

Activity

×
 

Activity

3.50
 

VKTX Activity Sentiment

 Insider selling during the past 3 months

 

Future

×
 

Future

3.00
 

VKTX Future Sentiment

 Earnings are forecast to decrease

VKTX Future Sentiment

 Trading below its fair value

VKTX Future Sentiment

 Outperform the market

 
 

VKTX Analysts Opinion

VKTX Analysts opinion is negative and it remained unchanged from the past 3 months

 

VKTX Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
81%
Buy
Opinion
Trend
Score
Potential
Score
 
 
NA
94%
56%
 
On Track
On Track
On Track
 

VKTX Street Opinion 

VKTX Street view is extremely ish and have positive views on the near-term outlook

 

VKTX Performance Sentiment

Sentiments overview associated with VKTX events and the stock performance.
 
81%
17%
Positive
Negative
47 out of 58
events present
10 out of 58
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

VKTX Earnings

The TTM reflects 12-month period, providing review of VKTX financial performance.

 
Millions of Dollars
TTM
2023
2022
CAGR
 

 
Total Revenue
-
 
 
Operating Exp
101
101
70
+20.12%
 
 
Operating Inc
-101
-101
-70
-
 
 
Net Interest Inc
15
15
2
+173.86%
 
 
Interest Inc
15
15
2
+173.86%
 
 
Other Income
-
-
-
 
 
EPS
-0.92
-0.91
-0.90
-
 
 
Next Earnings Date: Apr 24, 2024
 
 
Highlights
Last Modify
Price
% Change

 
Investors Selling
This Week
94.50
+11.11%
 
New Product
This Week
85.05
+121.02%
 
Insider Selling
1 Week Ago
35.74
-1.27%
 
Options Activity
2 Month Ago
21.67
+0.51%
 
 
 
joker
 
 
 
StocksRunner

Explore our VKTX Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored FDX Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our VKTX Daily Alerts

Access the exclusive insights that over 10,000+ subscribers value. Stay ahead in the stock market! Submit your email for daily alerts.

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo

StocksRunner

Get the pulse of the market

 
StocksRunner
 
 

Most Trending

 

-7.16%

 
 
 

+13.55%

 

-2.54%

 
 
 
 
 
 

Stock Insights

 
 
 
 

Strengths

 

VKTX Rewards

 Trading below its fair value

VKTX Rewards

 Outperform the market

 

Risk Analysis

 

VKTX Risk Analysis

 Earnings are forecast to decrease

VKTX Risk Analysis

 Insider selling during the past 3 months

 
 
 

VKTX Risk Level

 
 
 

The Indicator assigning VKTX risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
 
VKTX Risk Level
LOW
HIGH

Risk Volatility

 

VKTX has Low Risk Level. Click here to check what is your level of risk

 
 
 
 

Stock Analysis

 
 
 
 

VKTX

 

Viking Therapeutics

$ 91.34

 
+$6.12 | +7.18%
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  News  
 
  Updates  
 

 
joker
 
 
 
Open
$ 90.00
 
 
MKT CAP
$ 9.18B
 
High
$ 94.67
 
 
VOL
$ 11.56M
 
Low
$ 86.23
 
 
AVG VOL
$ 7.50M
 
 
 

VKTX Analysis

  Sign in to view Viking Therapeutics (VKTX) recommendation from the last 90 days from financial news and social media.
 
 

Chart

 
 

22.84

17.24

10.03

11

 
 
1month
3month
6month
1year
 
Total Return
VKTX
vs.
S&P500
 

 
1-week Return
+7.40%
 
+1.04%
 
 
5-week Return
+327.42%
 
+4.91%
 
 
10-week Return
+376.97%
 
+7.60%
 
 
 

VKTX Analysts Opinion

VKTX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

NA
 
 
 

Rating

×
 

Rating

NA
 
 

Momentum

×
 

Momentum

3.88
 

VKTX Momentum Sentiment

 Has been gaining momentum

 

Activity

×
 

Activity

3.50
 

VKTX Activity Sentiment

 Insider selling during the past 3 months

 

Future

×
 

Future

3.00
 

VKTX Future Sentiment

 Earnings are forecast to decrease

VKTX Future Sentiment

 Trading below its fair value

VKTX Future Sentiment

 Outperform the market

 
 

VKTX Analysts Opinion

VKTX Analysts opinion is negative and it remained unchanged from the past 3 months

 

VKTX Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
81%
Buy
Opinion
Trend
Score
Potential
Score
 
 
NA
94%
56%
 
On Track
On Track
On Track
 

VKTX Street Opinion 

VKTX Street view is extremely ish and have positive views on the near-term outlook

 
VKTX Performance Sentiment
Sentiments overview associated with VKTX events and the stock performance.
 
81%
17%
Positive
Negative
47 out of 58
events present
10 out of 58
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

VKTX Earnings

The TTM data reflects the most recent 12-month period, providing overview of VKTX financial performance.

 
Millions of Dollars
TTM
2023
2022
CAGR
 

 
Total Revenue
-
 
 
Operating Exp
101
101
70
+20.12%
 
 
Operating Inc
-101
-101
-70
-
 
 
Net Interest Inc
15
15
2
+173.86%
 
 
Interest Inc
15
15
2
+173.86%
 
 
Other Income
-
-
-
 
 
EPS
-0.92
-0.91
-0.90
-
 
 
Next Earnings Date: Apr 24, 2024
 
Highlights
Last Modify
Price
% Change

 
Investors Selling
This Week
94.50
+11.11%
 
New Product
This Week
85.05
+121.02%
 
Insider Selling
1 Week Ago
35.74
-1.27%
 
Options Activity
2 Month Ago
21.67
+0.51%
 
 
VKTX Latest News Feed

Viking Therapeutics emerges as a strong weight loss drug player — or takeover target. Some Wall Street analysts said Vikings experimental obesity treatment may be best-in-class following the release of midstage trial data.

Sun Mar 3, 2024

Activity

Viking Therapeutics: A Teachable Moment About Investing for the Long Term. On Tuesday Viking Therapeutics (NASDAQ: VKTX) a clinical-stage biotech specializing in treatments for metabolic diseases saw its stock price surge by a staggering 121% in

Thu Feb 29, 2024

Momentum

Viking Therapeutics stock dips after pricing $550M stock offering.

Thu Feb 29, 2024

Momentum

Viking Therapeutics Prices Public Offering Of About 6.47 Mln Shares At $85/shr. (RTTNews) - Viking Therapeutics Inc. (VKTX) announced the pricing of its underwritten public offering of about 6.47 million shares of its common stock at a price to

Thu Feb 29, 2024

Activity

Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock. ) a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders today announced the pricing of its  und

Thu Feb 29, 2024

Activity

Viking Therapeutics weight-loss drug data makes company takeover target. Viking Therapeutics Inc.s stock rose another 8% Wednesday to extend its week-to-date gains to 145% as analysts weighed in on its positive weight-loss drug news with some ish commenta

Wed Feb 28, 2024

Activity
Potential

Behind the Scenes of Viking Therapeuticss Latest Options Trends. Whales with a lot of money to spend have taken a noticeably bearish stance on Looking at options history for Viking Therapeutics (NASDAQ:) we detected 31 trades. If we consider the specif

Wed Feb 28, 2024

Activity
Activity
Potential

Viking Therapeutics: VK2735 Data Supports A Buyout.

Wed Feb 28, 2024

Activity

Viking Therapeutics: Impressive Obesity Data Puts VK2735 As The Lead Asset (Rating Upgrade).

Wed Feb 28, 2024

Potential

Viking Therapeutics Announces Proposed Public Offering of Common Stock. ) a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders today announced that it has commenced an underwritten

Tue Feb 27, 2024

Activity

Viking Therapeutics stock jumps 120% after positive weight loss drug trial results. Analysts have suggested that larger pharmaceutical companies could potentially move to acquire a company like Viking Therapeutics. 

Tue Feb 27, 2024

Activity
Momentum

Viking Therapeutics proposes $350M stock offering after shares more than double in value.

Tue Feb 27, 2024

Activity

Viking Therapeutics stock jumps 115% after positive weight loss drug trial results. Analysts have suggested that larger pharmaceutical companies could potentially move to acquire a company like Viking Therapeutics. 

Tue Feb 27, 2024

Activity
Momentum

Tuesdays ETF Movers: XBI GDXJ. In trading on Tuesday the SPDR S&.P Biotech ETF is outperforming other ETFs up about 4% on the day. Components of that ETF showing particular strength include shares of Viking Therapeutics up about 99.7% an

Tue Feb 27, 2024

Potential

Viking Therapeutics stock jumps 90% after positive weight loss drug trial results. Analysts have suggested that larger pharmaceutical companies could potentially move to acquire a company like Viking Therapeutics. 

Tue Feb 27, 2024

Activity
Momentum

Ozempic Wegovy competitor drug doubles Viking Therapeutics stock. The race is on to break up the current weight loss drug duopoly held by Novo Nordisk the manufacturer of Ozempic and Wegovy and Eli Lilly the maker of Zepbound. The latest contender San Die

Tue Feb 27, 2024

Activity

Viking Therapeutics shares surge on raised stock price target.

Tue Feb 27, 2024

Momentum

Viking Therapeutics stock doubles as investors cheer cheap entry to weight-loss drug craze. Viking Therapeutics Inc.s stock soared 100% early Tuesday after the company announced positive results from a Phase 2 trial of its weight-loss drug VK2735 a GLP-1

Tue Feb 27, 2024

Activity
Potential

Viking Therapeutics surges 80% on phase 2 obesity drug results.

Tue Feb 27, 2024

Momentum

Viking Therapeutics weight-loss drug succeeds in mid-stage study. Viking Therapeutics said on Tuesday its experimental drug to treat obesity helped achieve significant weight loss in a mid-stage study sending the drugmakers shares up more than 4

Tue Feb 27, 2024

Activity
Momentum

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity. Study Achieves Primary and all Secondary Endpoints Demonstrating Statistically Significant Reductions in

Tue Feb 27, 2024

Activity

Viking Therapeutics stock jumps 80% after positive weight loss drug trial results. Analysts have suggested that larger pharmaceutical companies could potentially move to acquire a company like Viking Therapeutics. 

Tue Feb 27, 2024

Activity
Momentum

Viking Therapeutics shares surge on positive trial results.

Tue Feb 27, 2024

Activity
Momentum

Viking Therapeutics Stock Surges 100% on Positive Weight-Loss Drug Trial. Patients see significant reductions in body weight during a study of a weight-loss drug developed by Viking Therapeutics the company says.#vikingtherapeutics

Tue Feb 27, 2024

Activity
Momentum

Viking Therapeutics stock doubles after company reports positive results in trial of weight-loss drug. Viking Therapeutics Inc.s stock soared 100% early Tuesday after the company announced positive results from a Phase 2 trial of its weight-loss drug VK27

Tue Feb 27, 2024

Activity

(VKTX) - Analyzing Viking Therapeuticss Short Interest. ) short percent of float has fallen 6.26% since its last report. The company recently reported that it has Short interest is the number of shares that have been sold short but have not yet been cov

Tue Feb 20, 2024

Activity
Momentum

Viking Therapeutics Reaches Analyst Target Price. In recent trading shares of Viking Therapeutics Inc (Symbol: VKTX) have crossed above the average analyst 12-month target price of $36.00 changing hands for $36.20/share. When a stock reaches th

Mon Feb 19, 2024

Potential

Viking Therapeutics gains amid renewed takeover speculation.

Fri Feb 16, 2024

Activity

viking therapeutics gains amid takeover speculation.

Wed Jan 31, 2024

Activity

smart money is betting big in vktx options. high-rolling investors have positioned themselves bearish on viking therapeutics (nasdaq:) and it'.s important for retail traders to take note. \this activity came to our attention today through benzinga�

Wed Jan 24, 2024

Potential
Potential

 
 
 
 
 

Score Tracker

 
 
 
Based on 58 events in the last 90 days from financial news and social media. Last updated Mar 4, 2024 19:26 Wall St. time
 
 

VKTX Total Score

 
 
 
 
 
 
 
StocksRunner

Discover VKTX Stock analysis and effective trading strategies with StocksRunner. Gain valuable insights into stock performance, market trends, and the future potential of VKTX. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our VKTX Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

VKTX Stock trends

VKTX Stock performance

VKTX Stock analysis

VKTX investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
Post ×
 
0/666
joker